药物诱导性痴呆症:使用FDA不良事件报告系统数据库的现实世界药物监测研究
Lisi Xu1,2, Ruonan Zhang1, Xiaolin Zhang1
1Department of the Second Cadre Ward, General Hospital of Northern Theater Command, Shenyang, China.
Therapeutic advances in neurological disorders
|January 30, 2025
概括
这项研究使用FDA数据确定了与痴呆风险相关的药物. 许多药物缺乏警告,强调需要加强监测和进一步研究,以确保患者的安全.
科学领域:
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
- 神经学 神经学
背景情况:
- 痴呆症是一个显著的不良事件 (AE),对药物诱导的数据有限.
- 美国食品和药物管理局的不良事件报告系统 (FAERS) 对于识别现实世界的药物安全信号至关重要.
研究的目的:
- 使用FAERS数据识别与痴呆症风险增加相关的药物.
- 分析与痴呆相关不良事件相关的趋势和特定药物类别.
主要方法:
- 使用不成比例分析对FAERS数据库 (2004年第一季度 - 2023年第四季度) 的二次分析.
- 通过监管活动医学词典 (MedDRA) 识别痴呆病例.
- 痴呆症相关药物的频率计数和分类.
主要成果:
- 报告了31,881起与痴呆症相关的副作用,显示出上升趋势,特别是在女性和65岁以上的人群中.
- 阿皮克萨班是报告数量最多的药物 (1631).
- 里瓦斯蒂格明,尼塞尔戈林,阿杜卡努马布,阿姆洛迪平/阿托瓦斯塔丁和二格米特林显示出最高的痴呆风险信号.
结论:
- 识别了与痴呆风险相关的药物,许多药物在标签上没有明确的警告.
- 强调需要加强对高风险人群的监测.
- 呼吁进行进一步的研究以确认关联并提高患者的安全性.
相关概念视频
Pharmacovigilance
770
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
770
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160
Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439
Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
Dementia
92
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
92


